Helsinn Boosts Oncology Portfolio with BridgeBio’s Infigratinib
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)
Published: 9 Apr-2021
DOI: 10.3833/pdr.v2021.i4.2604 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Helsinn Group has agreed to partner with QED Therapeutics, an affiliate of BridgeBio Pharma, to develop and commercialise the latter’s fibroblast growth factor receptors 1-3 (FGFR1-3) inhibitor, infigratinib, in oncology and all other indications except for skeletal dysplasias...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS